Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.070
-0.060 (-1.92%)
At close: Sep 24, 2026, 4:00 PM EDT
3.520
+0.450 (14.66%)
After-hours: Sep 24, 2026, 6:39 PM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Prime Medicine stock has a consensus rating of "Buy" and an average price target of $7.11. The average 1-year stock price forecast is 131.60% higher than the current stock price, while the lowest is $4.25 (+38.44%) and the highest is $11 (+258.31%).
Price Target: $7.11 (+131.60%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 9 | 10 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $6 | Buy | Maintains | $6 | +95.44% | Sep 24, 2026 |
| Chardan Capital | Chardan Capital | Buy Maintains $7 | Buy | Maintains | $7 | +128.01% | Aug 25, 2026 |
| BMO Capital | BMO Capital | Buy Initiates $9 | Buy | Initiates | $9 | +193.16% | Aug 18, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $8 | Buy | Maintains | $8 | +160.59% | Aug 10, 2026 |
Financial Forecast
Revenue This Year
11.77M
from 4.63M
Increased by 154.00%
Revenue Next Year
13.38M
from 11.77M
Increased by 13.75%
EPS This Year
-0.93
from -1.35
EPS Next Year
-0.88
from -0.93
EPS and Forward PE are based on non-GAAP adjusted numbers.